Research programme: stress protein immunomodulation therapy - Stressgen

Drug Profile

Research programme: stress protein immunomodulation therapy - Stressgen

Alternative Names: Stress protein allergy therapy - Stressgen; Stress protein asthma therapy - Stressgen

Latest Information Update: 09 Oct 2002

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nventa Biopharmaceuticals Corporation
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Hypersensitivity

Most Recent Events

  • 09 Oct 2002 Discontinued - Preclinical for Allergy in USA (unspecified route)
  • 09 Oct 2002 Discontinued - Preclinical for Asthma in USA (unspecified route)
  • 06 Oct 1999 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top